Legal & General Group Plc Has $242.15 Million Stake in IQVIA Holdings Inc. $IQV

Legal & General Group Plc decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,074,265 shares of the medical research company’s stock after selling 58,039 shares during the quarter. Legal & General Group Plc owned about 0.63% of IQVIA worth $242,150,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of IQV. Vanguard Group Inc. grew its holdings in IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares during the period. Alliancebernstein L.P. grew its holdings in IQVIA by 1.2% during the third quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after purchasing an additional 41,643 shares during the period. Boston Partners acquired a new position in IQVIA during the third quarter valued at approximately $676,698,000. Artisan Partners Limited Partnership grew its holdings in IQVIA by 4.9% during the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock valued at $652,246,000 after purchasing an additional 161,085 shares during the period. Finally, Invesco Ltd. grew its holdings in IQVIA by 15.3% during the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after purchasing an additional 367,204 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $165.97 on Thursday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a twelve month low of $136.41 and a twelve month high of $247.04. The firm’s 50 day moving average price is $169.80 and its two-hundred day moving average price is $196.48. The firm has a market cap of $27.70 billion, a P/E ratio of 20.57, a PEG ratio of 1.55 and a beta of 1.18.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the previous year, the firm posted $2.70 earnings per share. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on IQV shares. Citigroup decreased their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a report on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.